Fractyl Health, Inc. (NASDAQ:GUTS) Receives $5.40 Consensus Price Target from Analysts

Fractyl Health, Inc. (NASDAQ:GUTS) has been assigned a consensus rating of “Hold” from the five brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $5.40.

A number of brokerages have recently commented on GUTS. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th. Wall Street Zen raised shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Thursday, June 4th.

Fractyl Health Stock Performance

NASDAQ GUTS opened at $0.78 on Wednesday. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. Fractyl Health has a 1 year low of $0.38 and a 1 year high of $2.45. The company has a market capitalization of $123.11 million, a PE ratio of -0.60 and a beta of 2.34. The company has a fifty day moving average of $0.71 and a two-hundred day moving average of $1.06.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.23. As a group, analysts expect that Fractyl Health will post -0.6 earnings per share for the current year.

Insider Transactions at Fractyl Health

In other Fractyl Health news, Director William Bradley bought 68,493 shares of Fractyl Health stock in a transaction dated Wednesday, June 10th. The stock was acquired at an average cost of $0.73 per share, with a total value of $49,999.89. Following the completion of the acquisition, the director owned 84,622 shares of the company’s stock, valued at approximately $61,774.06. This represents a 424.66% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ian Sheffield bought 35,000 shares of Fractyl Health stock in a transaction dated Wednesday, June 10th. The stock was acquired at an average cost of $0.73 per share, with a total value of $25,550.00. Following the completion of the acquisition, the director directly owned 35,000 shares of the company’s stock, valued at approximately $25,550. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 171,493 shares of company stock valued at $127,150 over the last ninety days. Corporate insiders own 8.52% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. FNY Investment Advisers LLC purchased a new position in Fractyl Health during the third quarter worth about $31,000. Jane Street Group LLC purchased a new position in Fractyl Health during the second quarter worth about $31,000. Accredited Investors Inc. purchased a new position in Fractyl Health during the first quarter worth about $46,000. Scientech Research LLC purchased a new position in Fractyl Health during the third quarter worth about $49,000. Finally, Prelude Capital Management LLC purchased a new position in Fractyl Health during the third quarter worth about $55,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.